Business Standard

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Related News

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of Januvia.

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

Read more on:   
|
|

Read More

Fresenius Kabi Oncology soars on delisting plan

The promoter intends to pay an indicative price of Rs 130 per share to acquire the shares offered to it in the Delisting Offer

Quick Links

 

Market News

Investor awareness drives must focus on quality: Sebi chief

U K Sinha says 'just completing' numbers not good enough to address needs of investors

Gold edges up on improved demand amid overseas support

Standard gold adds Rs 30 to end at Rs 26,405 per 10 grams, silver adds Rs 200 to Rs 37,160 per kg

Kotak-ING Vysya merger: Old pvt banks get thumbs up

Many were up between 3-6%, even as an index tracking banking sector hit an all-time high

Sebi rebukes HSBC Securities, India Star in Global Offshore case

Securites and Exchange Board of India (Sebi) on Friday 'reprimanded' HSBC Securities and Capital Markets Pvt Ltd for failing to make adequate ...

YES surges 4% as RBI allows FIIs to buy equity

Shares of YES Bank rose about four per cent on Friday, adding Rs 1,167.16 crore to its market valuation, after the Reserve Bank said FIIs can ...

Back to Top